Compare BWAY & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | IVVD |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.8M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | BWAY | IVVD |
|---|---|---|
| Price | $13.77 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $13.25 | $8.75 |
| AVG Volume (30 Days) | 91.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $314.08 | $143.48 |
| Revenue Next Year | $23.37 | $25.40 |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $7.84 | $0.46 |
| 52 Week High | $26.63 | $3.07 |
| Indicator | BWAY | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 57.57 |
| Support Level | $11.55 | $1.41 |
| Resistance Level | $17.20 | $2.01 |
| Average True Range (ATR) | 1.13 | 0.11 |
| MACD | -1.20 | 0.05 |
| Stochastic Oscillator | 16.10 | 80.90 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.